2300 Lakeview Parkway, #700, Alpharetta, GA 30009, USA

 

info@maxinib.com

Tel: +1 (508) 219-0200

 

POWERFUL EFFICACY TO FIGHT AGAINST RCC

FIRST-LINE TREATMENT In Management of Renal Cell Carcinoma

Practice Guidelines in Oncology 2017

First-line treatment of patients

with good or intermediate prognosis

Sunitinib is listed as a first-line therapy options for patients with relapsed or stage IV and surgically unresectable with predominantly clear cell renal cell carcinoma.

Only Sunitinib was listed as the “preferred” option for systemic therapy options for relapsed or stage IV and surgically unresectable with nonclear cell histology.

The usual dose is 50 mg once daily taken for 28 days (4 weeks), followed by 14 days  (2 weeks) of rest (drug-free).

 

Dose modification renal cell carcinoma (RCC).

 

• Increase or reduce dose in 12.5-mg increments based on individual safety  and tolerability.

 

• Concurrent CYP3A4 Inhibitors: Consider dose reduction to 37.5 mg once daily 

 

• Concurrent CYP3A4 Inducers: Consider dose increase not to exceed  87.5 mg once daily 

 

(Sunitinib)

(Sunitinib)

 Multi-targeted receptor tyrosine kinase inhibitor.

• Sunitinib simultaneously inhibits PDGF and VEGF receptors, which play a role in both tumor cell proliferation and angiogenesis.

• Sunitinib induces tumor regression and inhibits angiogenesis and metastatic progression.

is perfectly equivalent to the reference drug.